Eiger BioPharmaceuticals announces 1-for-30 reverse stock split

Eiger BioPharmaceuticals announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The company’s common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the company’s plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Global Market, among other benefits.